Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)

LEUKEMIA

SPRINGERNATURE

1. Celgene
2. Swedish Cancer Society
3. Nordic Cancer Union